Is C-Reactive Protein a Specific Marker in Melanoma?

被引：4

作者：

Li, Zhi ^{[1
]}

Feng, Jiexiong ^{[1
]}

Sun, Xiaoyi ^{[1
]}

机构：

[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan 430074, Hubei, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 31期

关键词：

STAGE-IV; SURVIVAL; CANCER; SERUM;

D O I：

10.1200/JCO.2015.62.2696

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3673 / +

页数：2

共 10 条

[1] Baseline C-Reactive Protein Is Associated With Incident Cancer and Survival in Patients With Cancer [J].

Allin, Kristine H. ;

Bojesen, Stig E. ;

Nordestgaard, Borge G. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (13) :2217-2224

[2] C-reactive protein [J].

Black, S ;

Kushner, I ;

Samols, D .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (47) :48487-48490

[3] C-Reactive Protein and Risk of Lung Cancer [J].

Chaturvedi, Anil K. ;

Caporaso, Neil E. ;

Katki, Hormuzd A. ;

Wong, Hui-Lee ;

Chatterjee, Nilanjan ;

Pine, Sharon R. ;

Chanock, Stephen J. ;

Goedert, James J. ;

Engels, Eric A. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) :2719-2726

[4] The C-reactive protein [J].

Clyne, B ;

Olshaker, JS .

JOURNAL OF EMERGENCY MEDICINE, 1999, 17 (06) :1019-1025

[5] Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase [J].

Deichmann, M ;

Kahle, B ;

Moser, K ;

Wacker, J ;

Wüst, K .

BRITISH JOURNAL OF CANCER, 2004, 91 (04) :699-702

[6] C-Reactive Protein As a Marker of Melanoma Progression [J].

Fang, Shenying ;

Wang, Yuling ;

Sui, Dawen ;

Liu, Huey ;

Ross, Merrick I. ;

Gershenwald, Jeffrey E. ;

Cormier, Janice N. ;

Royal, Richard E. ;

Lucci, Anthony ;

Schacherer, Christopher W. ;

Gardner, Julie M. ;

Reveille, John D. ;

Bassett, Roland L. ;

Wang, Li-E ;

Wei, Qingyi ;

Amos, Christopher I. ;

Lee, Jeffrey E. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (12) :1389-+

[7] Serum Amyloid A As a Prognostic Marker in Melanoma Identified by Proteomic Profiling [J].

Findeisen, Peter ;

Zapatka, Marc ;

Peccerella, Teresa ;

Matzk, Heike ;

Neumaier, Michael ;

Schadendorf, Dirk ;

Ugurel, Selma .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (13) :2199-2208

[8] Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: Prognostic value of interleukin-6-from the Groupe Francais d'Immunotherapie [J].

Negrier, S ;

Perol, D ;

Menetrier-Caux, C ;

Escudier, B ;

Pallardy, M ;

Ravaud, A ;

Douillard, JY ;

Chevreau, C ;

Lasset, C ;

Blay, JY .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2371-2378

[9] A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma [J].

Tarhini, Ahmad A. ;

Lin, Yan ;

Yeku, Oladapo ;

LaFramboise, William A. ;

Ashraf, Madeeha ;

Sander, Cindy ;

Lee, Sandra ;

Kirkwood, John M. .

JOURNAL OF TRANSLATIONAL MEDICINE, 2014, 12

[10] Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma [J].

Tarhini, Ahmad A. ;

Cherian, John ;

Moschos, Stergios J. ;

Tawbi, Hussein A. ;

Shuai, Yongli ;

Gooding, William E. ;

Sander, Cindy ;

Kirkwood, John M. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (03) :322-328

← 1 →